Life Biosciences Strengthens Board Of Directors With Appointment Of David Guyer, M.D.

Life Biosciences, a biotechnology company pioneering cellular rejuvenation therapies aimed at reversing and preventing multiple diseases of aging, has announced the appointment of David Guyer, M.D., to its Board of Directors, effective November 1, 2025. Dr. Guyer is an accomplished biotechnology leader and physician-entrepreneur with more than three decades of experience in drug development, commercialization, and value creation across the life sciences industry.

Dr. Guyer currently serves as the co-founder, president, and chief executive officer of EyeBio, a subsidiary of Merck & Co., Inc. Over his distinguished career, he has led several biotechnology companies, both public and private, and played a pivotal role in bringing breakthrough therapies to market. His extensive leadership background includes serving as a venture partner at SV Health Investors and as a professor and chairman of the Department of Ophthalmology at New York University School of Medicine.

Notably, Dr. Guyer co-founded and served as CEO of Eyetech Pharmaceuticals, where he led the development and commercialization of the first anti-VEGF (vascular endothelial growth factor) drug for macular degeneration—an innovation that transformed the treatment of retinal disease. His achievements also include taking two companies public, overseeing multiple mergers and acquisitions, and serving on more than 25 corporate boards. Most recently, in July 2024, he oversaw the acquisition of EyeBio by Merck & Co., Inc.

Dr. Guyer earned his Bachelor of Science degree from Yale College and his Doctor of Medicine degree from the Johns Hopkins University School of Medicine. He completed his ophthalmology residency at the Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Commenting on the appointment, Jerry McLaughlin, Chief Executive Officer of Life Bio, said, “We are delighted to welcome David to our Board of Directors. David has been a trusted advisor to Life Bio for several years, and as a Board member, he will bring exceptional scientific, operational, and governance expertise. His insights into translational development and strategic value creation will be instrumental as we advance Life Bio’s platform and pipeline. I look forward to his guidance as we initiate human trials for ER-100 in the first quarter of 2026 and continue exploring new indications using our partial epigenetic reprogramming platform.”

Expressing his enthusiasm about joining the Board, Dr. Guyer said, “Life Bio’s innovative approach to reversing age-related diseases through cellular rejuvenation is truly compelling. Having worked with the company for several years, I have been consistently impressed by the leadership team’s focus and progress in developing its partial epigenetic reprogramming platform. While my clinical background in ophthalmology aligns naturally with Life Bio’s work in ophthalmic indications, I look forward to contributing my broader experience in biotechnology to help expand this promising platform across multiple organ systems.”

In conjunction with Dr. Guyer’s appointment, Life Bio announced that Bracken Darrell has stepped down from the Board of Directors, effective November 1, 2025. Mr. Darrell, who joined the Board in 2018, provided significant leadership and strategic direction during a period of substantial growth for the company.

David Sinclair, Ph.D., Co-founder and Board Chair of Life Bio, expressed his appreciation, stating, “We are thrilled to welcome David to our Board. His experience and insight will be invaluable as we continue to advance our mission to reverse the biology of aging. On behalf of the Board and management team, I would also like to thank Bracken for his years of dedicated service, guidance, and support. We wish him continued success in all his future endeavors.”

With Dr. Guyer’s appointment, Life Biosciences strengthens its Board with deep scientific and business expertise as it continues to advance its pioneering work in cellular rejuvenation and develop next-generation therapies to combat age-related diseases.